Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 9/2018

Open Access 01-09-2018 | Original Article

Nontuberculous mycobacterial disease managed within UK primary care, 2006–2016

Authors: Eleanor L. Axson, Chloe I. Bloom, Jennifer K. Quint

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 9/2018

Login to get access

Abstract

Previous UK studies investigating nontuberculous mycobacteria have been limited to reporting isolation from culture, not burden of disease. We assessed the burden of nontuberculous mycobacterial disease (NTMD) in UK primary care from 2006 to 2016. Using electronic healthcare records, we identified patients with NTMD using a strict definition including patients with guideline-directed treatment/monitoring. We described treatment regimens and incidence/prevalence in the general population and in patients with underlying chronic respiratory diseases. Incidence of primary care-managed NTMD in the general population decreased (2006 to 2016 rates per 100,000 person-years, 3.85 to 1.28). Average annual prevalence of NTMD in the general population was 6.38 per 100,000. Around 85% were taking antimycobacterial therapy; 53.2% were taking a guideline-recommended regimen. Incidence of NTMD in patients with respiratory disease decreased (2006 to 2016 rates per 100,000 person-years, 12.5 to 7.40). Average annual prevalence of NTMD in patients with respiratory disease was 27.7 per 100,000. This is the first UK study using nationally representative data to investigate the burden of NTMD managed within primary care. Incidence and prevalence of managed NTMD within primary care is gradually declining. Increasing complexity in the management of NTMD may be driving a shift in care to secondary settings.
Appendix
Available only for authorised users
Literature
1.
go back to reference Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K, Subcommittee ATSMD, American Thoracic S, Infectious Disease Society of A (2007) An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175(4):367–416. https://doi.org/10.1164/rccm.200604-571ST CrossRefPubMed Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K, Subcommittee ATSMD, American Thoracic S, Infectious Disease Society of A (2007) An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175(4):367–416. https://​doi.​org/​10.​1164/​rccm.​200604-571ST CrossRefPubMed
2.
go back to reference Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, Ormerod P, Shingadia D, Smith S, Whitehead N, Wilson R, Floto RA, BTS NTM Guideline Development Group on behalf of the British Thoracic Society (2017) British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 72(Supplement 2):ii1–ii64 Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, Ormerod P, Shingadia D, Smith S, Whitehead N, Wilson R, Floto RA, BTS NTM Guideline Development Group on behalf of the British Thoracic Society (2017) British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 72(Supplement 2):ii1–ii64
3.
go back to reference Moore J, Kruijshaar M, Ormerod LP, Drobniewski F, Abubakar I (2010) Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995–2006. BMC Public Health 10:612CrossRefPubMedPubMedCentral Moore J, Kruijshaar M, Ormerod LP, Drobniewski F, Abubakar I (2010) Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995–2006. BMC Public Health 10:612CrossRefPubMedPubMedCentral
12.
go back to reference Campbell I, Drobniewski F, Novelli V, Ormerod P, Pozniak A, Society SotJTCotBT (2000) Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 55:210–218CrossRef Campbell I, Drobniewski F, Novelli V, Ormerod P, Pozniak A, Society SotJTCotBT (2000) Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 55:210–218CrossRef
13.
22.
35.
go back to reference Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, Ormerod P, Shingadia D, Smith D, Whitehead N, Wilson R, Floto RA (2017) British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). BMJ Open Respir Res 4(1). https://doi.org/10.1136/bmjresp-2017-000242 Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, Ormerod P, Shingadia D, Smith D, Whitehead N, Wilson R, Floto RA (2017) British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). BMJ Open Respir Res 4(1). https://​doi.​org/​10.​1136/​bmjresp-2017-000242
39.
go back to reference Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18:254–261CrossRefPubMed Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18:254–261CrossRefPubMed
Metadata
Title
Nontuberculous mycobacterial disease managed within UK primary care, 2006–2016
Authors
Eleanor L. Axson
Chloe I. Bloom
Jennifer K. Quint
Publication date
01-09-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 9/2018
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-018-3315-6

Other articles of this Issue 9/2018

European Journal of Clinical Microbiology & Infectious Diseases 9/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.